.jpg)
Theia
In a blinded, observational clinical study approved by the Spanish Agency of Medicines and Medical Devices (AEMPS), Theia demonstrated strong diagnostic performance in detecting mild cognitive impairment (MCI). The study included 60 participants (30 MCI patients and 30 healthy controls), with additional external validation on an independent cohort of 40 subjects.
Sensitivity: 80%
Specificity: 94%
These results indicate that Theia is highly effective at correctly identifying healthy individuals while maintaining robust sensitivity for detecting MCI.
Theia is designed for routine use in clinical and healthcare settings as an objective brain assessment tool. It can be applied in neurology, geriatrics, psychiatry, and psychology clinics to support the early detection and monitoring of mild cognitive impairment and other cognitive or mental health conditions.
In practice, Theia is used during standard cognitive tasks to provide quantitative brain biomarkers that complement traditional neuropsychological assessments. Its portability and non-invasive nature make it suitable for outpatient clinics, primary care settings, memory units, and clinical research environments, enabling faster evaluations, improved diagnostic confidence, and better-informed clinical decision-making.
